US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onestream Inc

28.24

+0.73002.65%

Post-market: 28.240.00000.00%18:55 EDT

Volume:931.55K

Turnover:26.30M

Market Cap:4.98B

PE:-15.98

High:28.48

Open:27.90

Low:27.65

Close:27.51

Loading ...

Overview Company News Filings

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Q4 2024 Hackett Group Inc Earnings Call

Thomson Reuters StreetEvents

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

INAB: Continued Survival in INB-100 Trial

Zacks Small Cap Research

OneStream to Participate in Upcoming Investor Conference

Analysts Offer Insights on Technology Companies: Onestream, Inc. Class A (OS) and Super Micro Computer (SMCI)

OneStream Is Maintained at Overweight by Morgan Stanley

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Why OneStream Inc. (OS) Crashed on Wednesday

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

OneStream Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

Onestream Inc. A: Positive Earnings Call Insights

Why OneStream Inc. (OS) Stock Is Crashing Today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OS/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"Onestream Inc","latestPrice":28.24,"timestamp":1750104000000,"preClose":27.51,"halted":0,"volume":931547,"hourTrading":{"tag":"盘后","latestPrice":28.24,"preClose":28.24,"latestTime":"18:55 EDT","volume":50370,"amount":1422434.06,"timestamp":1750114527181},"delay":0,"floatShares":69131974,"shares":176260091,"eps":-1.766751,"marketStatus":"Not Yet Opened","change":0.73,"latestTime":"06-16 16:00:00 EDT","open":27.9,"high":28.475,"low":27.65,"amount":26302699.044687998,"amplitude":0.029989,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.766751,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750147200000},"marketStatusCode":0,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":27.51,"preHourTrading":{"tag":"盘前","latestPrice":28.35,"preClose":27.51,"latestTime":"09:28 EDT","volume":177,"amount":4909.08969,"timestamp":1750080480077},"postHourTrading":{"tag":"盘后","latestPrice":28.24,"preClose":28.24,"latestTime":"18:55 EDT","volume":50370,"amount":1422434.06,"timestamp":1750114527181},"volumeRatio":0.759035,"impliedVol":0.5835,"impliedVolPercentile":0.5385},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":69131974,"roa":"-35.83%","roe":"-108.78%","lyrEps":-1.232998,"volumeRatio":0.759035,"shares":176260091,"dividePrice":0,"high":28.475,"amplitude":0.029989,"preClose":27.51,"low":27.65,"week52Low":16.6942,"pbRate":"12.06","psRate":"9.66","week52High":35.39,"institutionHeld":0,"latestPrice":28.24,"eps":-1.766751,"divideRate":0,"volume":931547,"delay":0,"ttmEps":-1.766751,"open":27.9,"prevYearClose":28.52,"prevWeekClose":27.51,"prevMonthClose":28.06,"prevQuarterClose":21.34,"fiveDayClose":28.92,"twentyDayClose":28.27,"sixtyDayClose":22.17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514186726","title":"Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27","url":"https://stock-news.laohu8.com/highlight/detail?id=2514186726","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514186726?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:01","pubTimestamp":1740603660,"startTime":"0","endTime":"0","summary":"NEW YORK, February 26, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar on February 27, 2025, at 4:15 p.m. ET.The exclusive event, hosted by RedChip Companies, will feature OS Therapies’ Chairman and CEO, Paul Romness, and Chief Business Officer, Gerald Commissiong, who will provide an in-depth update on the Company’s rapidly advancing pipeline. OS Therapies is pioneering groundbreaking immunotherapies and antibody-drug conjugates  to address critical unmet needs in pediatric and young adult oncology, as well as a broad range of solid tumors. The Company’s lead candidate, OST-HER2, has demonstrated statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic osteosarcoma, positioning it as a potential first-in-class treatment with accelerated FDA approval pathways. Additionally, OS Therapies’ proprietary Tunable Antibody Drug Conjug","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-os-therapies-exclusive-live-210100765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OS","BK4097","BK4231","ADC","BK4080","OSTX"],"gpt_icon":0},{"id":"2514853387","title":"MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853387","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853387?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:47","pubTimestamp":1740577620,"startTime":"0","endTime":"0","summary":"Expansion study to enroll patients in the U.S. and select countries in Europe and Asia. CHICAGO, February 26, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer . Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates  in advanced NSCLC patients receiving third line  therapy who were resistant to previous checkpoint inhibitor treatments  and chemotherapy.MAIA recently announced an amended clinical supply agreement with Regeneron to include the expansion portion of THIO-101. Under terms of the amended agreement, MAIA continues to sponsor THIO-101 and Regeneron will provide Libtayo for the treatment of all patients including the additional patients in the expansion and potentially, the registration studies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-design-expansion-134700870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","IE00B19Z3B42.SGD","L","LU1261432733.SGD","LU0053666078.USD","LU0868494617.USD","LU1059921491.USD","BK4585","IE00BSNM7G36.USD","CPI","IE0002270589.USD","IE00B7SZL793.SGD","LU0289739699.SGD","BK4588","BK4196","BK4097","IE00B66KJ199.SGD","ORR","LU0058720904.USD","OS","AEIS","MAIA","IE0031619046.USD","BK4107","BK4157","IE00B19Z3581.USD","CI","BK4139"],"gpt_icon":0},{"id":"2514483443","title":"Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2514483443","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514483443?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:30","pubTimestamp":1740573000,"startTime":"0","endTime":"0","summary":"Achieved $47.5 million in RYTELO  net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval. Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met. FOSTER CITY, Calif., February 26, 2025----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights.Continued execution on U.S. commercial launch, with net product revenue for RYTELO  of $47.5 million in the fourth quarter of 2024 and $76.5 million since launch at the end of June 2024, following approval by the U.S. Food and Drug Administration .Presented new data at the 66th American Society for Hematology  Annual Meeting in December 2024, including analyses of IMerge Phase 3 data suggesting clinical activity o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-reports-fourth-quarter-123000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHMP","BK4097","BK4109","LU2463526074.USD","OS","ASH","GERN","BK4087","BK4139"],"gpt_icon":0},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4599","PROC","BK4533","BK4548","LU1721428933.USD","LU2413666699.HKD","BK4121","LU0347712357.USD","IE00B19Z4B17.USD","IMCR","IE0031619046.USD","BK4567","BK4585","BK4195","LU1093756325.SGD","ORR","LU2065731478.USD","PFS","BK4505","BK4097","BK4211","OS","ALT","BK4007","MTD","IE00B7SZL793.SGD","CRS","BK4588","CTA","IE00BYQQ9H92.USD","LU1093756168.USD","CM","ATOM","IE00B66KJ199.SGD","LU1878469433.USD","IE00BFXG0V08.USD","BK4207","BK4139","LU2413666426.HKD","BK4147"],"gpt_icon":0},{"id":"2514831987","title":"Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2514831987","media":"Business Wire","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514831987?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"First and only next-generation oral SERD and complete ER antagonist to demonstrate 1st-line benefit in combination with widely approved CDK4/6 inhibitors. The key secondary endpoints of time to second disease progression  and overall survival  were immature at the time of this interim analysis. However, the camizestrant combination demonstrated a trend toward improvement in PFS2. The trial will continue as planned to further assess key secondary endpoints.Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca, said: \"These impressive results demonstrate the versatility of camizestrant in combination with all the widely approved CDK4/6 inhibitors to provide a well-tolerated new potential treatment option in the first-line setting for the one in three patients with HR-positive, HER2-negative advanced breast cancer whose tumors develop ESR1 mutations during","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/camizestrant-demonstrated-highly-statistically-significant-120000062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","LU1829250122.USD","LU2456880835.USD","III","BK4134","BK4568","LU0320765992.SGD","LU0109394709.USD","HR","LU2462157665.USD","BK4585","LU2236285917.USD","PFS","BK4588","LU2417539215.USD","BK4225","BK4203","OS","BK4007","BK4097","LU0889565916.HKD","BK4211","AZN"],"gpt_icon":0},{"id":"2513726307","title":"PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726307?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"Data confirms Versamune HPV has potential as a broadly effective treatment of HPV16-associated cancers –Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025. Versamune HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells  vs. CRT alone. 100% of patients with locally advanced HPV16 cervical cancer treated with Versamune HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT. Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival  of 93% vs only 30% in patients with detectable HPV ctDNA. A total of 66 patients with locally advanced cervical cancer were enrolled, with 49 receiving CRT and 17 receiving a combination of CRT and Versamune HPV. Patient blood was collected at baseline, weeks 1, 3, and 5 of CRT, and 3 to 4 months after CRT to measure HPV ctDNA. MRI was performed at baseline and before brachytherapy to determine tumor sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pds-biotech-announces-circulating-tumor-130000736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRT","BK4213","BK4139","DNA","BK4109","PDS","BK4231","OS","BK4080","ADC","BK4097","PDSB","BK4092"],"gpt_icon":0},{"id":"2512432823","title":"Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512432823","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512432823?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:14","pubTimestamp":1739999669,"startTime":"0","endTime":"0","summary":"On Wednesday, Bristol Myers Squibb& Co  announced the final analysis of overall survival  from the Phase 3 CheckMate -816 study, which evaluatedOpdivo  in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small cell lung cancer .Also Read: Trump’s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich. The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.The results build on the previously reported primary endpoints of event-free survival  and pathological complete response , which also met statistical significance.The safety profile ofOpdivoin combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-cancer-drug-opdivo-211429682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","ALK","LU0225284248.USD","LU0321505868.SGD","LU1868837300.USD","LU1093756168.USD","BK4585","LU1032466523.USD","BK4500","LU0096364046.USD","ORR","LU0061475181.USD","LU2360032135.SGD","LU0225771236.USD","BK4126","LU1074936037.SGD","IE0002141913.USD","LU2125154778.USD","LU1261432733.SGD","LU1430594728.SGD","IE0009355771.USD","LU1291159041.SGD","LU1670711123.USD","IE00BFTCPJ56.SGD","BK4008","IE00BSNM7G36.USD","LU0321505439.SGD","LU1989771016.USD","LU1718418525.SGD","IE00BJJMRZ35.SGD","LU1868836757.USD","LU2242652126.USD","LU1585245621.USD","LU2133065610.SGD","BK4559","LU1868836914.USD","LU1868836591.USD","LU1670710661.SGD","LU2125154935.USD","MYE","BMY","LU1323610961.USD","LU1670711040.USD","LU0868494617.USD","LU1670710588.SGD","LU1093756325.SGD","IE00BJT1NW94.SGD","LU0306807586.USD","LU0306806265.USD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2512482419","title":"Q4 2024 Hackett Group Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2512482419","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512482419?lang=en_us&edition=fundamental","pubTime":"2025-02-20 00:52","pubTimestamp":1739983960,"startTime":"0","endTime":"0","summary":"Robert Ramirez; Chief Financial Officer, Executive Vice President - Finance; Hackett Group Inc. Ted Fernandez; Chairman of the Board, Chief Executive Officer; Hackett Group Inc. Thank you, Rob, and welcome, everyone, to our fourth quarter earnings call. As we normally do, I'll open the call with some overview comments on the quarter. I will then turn it back over to Rob to comment on detailed operating results, cash flow and guidance. We will then review our market and strategy-related comments, after which we will open it up to Q&A. This afternoon, we reported total revenues of $79.2 million and adjusted earnings per share of $0.47, both exceeding our quarterly guidance. Our results were driven by the overperformance of our SAP segment and the strong performance of our GSBT segment, which continued to see increased revenue growth from our GenAI engagements. GenAI revenues have a higher margin than our traditional consulting and implementation revenues and are driven by highly differen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-hackett-group-inc-165240034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORCL","OS","HCKT"],"gpt_icon":0},{"id":"2512104071","title":"Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2512104071","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512104071?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:30","pubTimestamp":1739968200,"startTime":"0","endTime":"0","summary":"– Total Revenue of $145 Million and U.S. XPOVIO  Net Product Revenue of $113 Million for Full Year 2024 –。–Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Nave Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 –。–Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkpoint Inhibitors. Increasing Sample Size to 276; Top-Line Data Now Expected in Mid-2026 –。– Company Provides Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million –","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/karyopharm-reports-fourth-quarter-full-123000326.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/karyopharm-reports-fourth-quarter-full-123000326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PRGS","OS","LU0054578231.USD","PFS","ITT","LU2065732104.USD","BK4139","EC","BK4201","BK4211","BK4195","LU0053671581.USD","KPTI","BK4161","BK4097"],"gpt_icon":0},{"id":"2512484426","title":"INAB: Continued Survival in INB-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512484426","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512484426?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:11","pubTimestamp":1739963460,"startTime":"0","endTime":"0","summary":"IN8bio, Inc  updates survival data for its INB-100 trial in a February 11thpress release in preparation for presentation of data at the Transplantation & Cellular Therapy  Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17th, 2025. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of progression free survival  and overall survival . Since our last update, IN8bio has participated in multiple investor and scientific conferences, including Biotech Showcase, Noble’s Emerging Growth Conference, the American Society of Hematology Annual Meeting and the TCT meetings.The results are remarkable as real-world survival rates for AML patients following hematopoietic stem cell transplantation  are lower. For example, the Center for International Blood and Marrow Transplant Research  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-continued-survival-inb-100-111100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BK4161","CR","BK4539","LU2065731478.USD","IE00B7SZL793.SGD","HSCT","IE0031619046.USD","BK4139","OS","INB","IE00B66KJ199.SGD","BK4006","CRS","BK4211","IE00B19Z4B17.USD","PFS","BK4195","INAB"],"gpt_icon":0},{"id":"2512895116","title":"OneStream to Participate in Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2512895116","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512895116?lang=en_us&edition=fundamental","pubTime":"2025-02-19 07:00","pubTimestamp":1739919600,"startTime":"0","endTime":"0","summary":"BIRMINGHAM, Mich., Feb. 18, 2025 /PRNewswire/ -- OneStream, Inc. , the leading enterprise Finance management platform that modernizes the Office of the CFO by unifying core finance and operational functions -- including financial close, consolidation, reporting, planning and forecasting -- today announced that it will be presenting at the Morgan Stanley Technology, Media & Telecom Conference on Tuesday, March 4, at 11:30 a.m. ET / 8:30 a.m. PT in San Francisco, CA.OneStream is how today's Finance teams can go beyond just reporting on the past and Take Finance Further by steering the business to the future. It's the leading enterprise finance platform that unifies financial and operational data, embeds AI for better decisions and productivity, and empowers the CFO to become a critical driver of business strategy and execution.We deliver a comprehensive cloud-based platform to modernize the Office of the CFO. Our Digital Finance Cloud unifies core financial and broader operational data a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onestream-participate-upcoming-investor-conference-230000607.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-participate-upcoming-investor-conference-230000607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1732800096.USD","LU2347655156.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","LU1989772923.USD","BK4516","LU0106831901.USD","LU1732799900.SGD","LU2111349929.HKD","LU0971096721.USD","LU0158827948.USD","LU0106261372.USD","LU0158827781.USD","LU2089283258.USD","BK4585","LU2271345857.HKD","LU0320765646.SGD","LU0098860793.USD","LU2133065610.SGD","BK4581","LU1720051017.SGD","LU0795875169.SGD","LU2028103732.USD","BK4504","LU2023251221.USD","LU1363072403.SGD","BK4534","LU0225283273.USD","BK4588","LU0795875086.SGD","LU1074936037.SGD","LU2357305700.SGD","LU1162221912.USD","BK4127","LU1989772840.SGD","LU1720051108.HKD","OS","BK4097","IE00BZ1G4Q59.USD","LU0006306889.USD","LU1548497426.USD","LU0912757837.SGD","LU2089284900.SGD","LU0267386448.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2512940315","title":"Analysts Offer Insights on Technology Companies: Onestream, Inc. Class A (OS) and Super Micro Computer (SMCI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512940315","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512940315?lang=en_us&edition=fundamental","pubTime":"2025-02-17 21:32","pubTimestamp":1739799149,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Technology sector with new ratings on Onestream, Inc. Class A (OS – Research Report) and Super Micro Co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-onestream-inc-class-a-os-and-super-micro-computer-smci?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-technology-companies-onestream-inc-class-a-os-and-super-micro-computer-smci?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","OS","BK4097","LU0053671581.USD","BK4543","LU1861215975.USD","LU1861220033.SGD","SMCI","BK4588","BK4170"],"gpt_icon":0},{"id":"2511699036","title":"OneStream Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2511699036","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511699036?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:54","pubTimestamp":1739544840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 14, 2025 09:54 ET (14:54 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS"],"gpt_icon":0},{"id":"2511569349","title":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2511569349","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511569349?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:00","pubTimestamp":1739541600,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 14, 2025  -- February 14, 2025– IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy  Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia  patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology.The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival  rate across all leukemia patients stands at 90.9%, and 1-year overall survival  is 100%, outperforming real-world historical controls. These data demonstrate that results for INB-100 do not appear to be due to imbalances in pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-presents-positive-phase-1-140000114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00B66KJ199.SGD","BK4195","IE0031619046.USD","OS","BK4006","BK4539","PFS","BK4097","BK4211","INAB","IE00B19Z4B17.USD","LU2065731478.USD","CRS","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2511085575","title":"Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2511085575","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511085575?lang=en_us&edition=fundamental","pubTime":"2025-02-14 05:30","pubTimestamp":1739482200,"startTime":"0","endTime":"0","summary":"Efficacy Comparable to Approved Autologous CD19 CAR Ts:Achieved Overall Response  and Complete Response  Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal Study Regimen, Respectively. Durability of Response:Among Patients Who Achieved CR, Median Duration of Response  of 23.1 Months and Median Overall Survival  Not Reached. Foundation for Cema-Cel in ALPHA3 Trial in First Line  Consolidation: Achieved 100% CR in Patients with Low Disease Burden. \"With multiple patients in ongoing complete remissions beyond four years, the lingering question of whether an allogeneic CAR T could deliver durable responses has now been answered,\" said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research and Development and Chief Medical Officer of Allogene. \"Furthermore, these results provide potent evidence supporting the use of CAR T in patients with low disease burden and the unique opportunity for the ALPHA3 trial to achieve something novel in this disease – predict and inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-announces-publication-durable-213000140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLO","BK4139","OS","BK4022","IE00B19Z4B17.USD","LU2065731478.USD","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","BK4097","ORR","CAR","CRS","SOC","BK4161","BK4230","BK4006","BK4505","BK4213","CR"],"gpt_icon":0},{"id":"2511544953","title":"Why OneStream Inc. (OS) Crashed on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2511544953","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511544953?lang=en_us&edition=fundamental","pubTime":"2025-02-13 20:26","pubTimestamp":1739449600,"startTime":"0","endTime":"0","summary":"Wall Street’s major indices finished mixed on Wednesday, though generally pessimistic, as investor sentiment was dampened by higher-than-expected consumer price data which fueled concerns of a potential inflation rebound.The Dow Jones and S&P 500 declined by 0.50 percent and 0.27 percent, respectively. Only Nasdaq posted gains, albeit a marginal 0.03 percent.Among Wednesday’s losers, 10 companies were the worst performers, primarily due to disappointing earnings results, dismal outlook guidance, and downgraded ratings, among others. In this article, we have detailed the specific reasons behind their lagging performance.To come up with Wednesday’s top losers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.An expert in the field of finance researching new markets and investment opportunities.OneStream Inc. nosedived by 19.91 percent on Wednesday to close at $24.17 per share following a downgraded outlook from an inve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-onestream-inc-os-crashed-122640552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","NQmain","QID","OS","QLD",".IXIC","TQQQ","SQQQ","MNQmain","USJW.SI","NVIW.SI","PSQ","BK4097","USAW.SI"],"gpt_icon":1},{"id":"2511439985","title":"IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511439985","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511439985?lang=en_us&edition=fundamental","pubTime":"2025-02-13 19:05","pubTimestamp":1739444700,"startTime":"0","endTime":"0","summary":"Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025. 95 patients enrolled in neoadjuvant UM trial and targeting clinical data and regulatory update in H1 2025, including vision data in plaque brachytherapy patients. Targeting median OS readout in ~40 1L MUM patients in 2025. Targeting expansion of study in Q1 2025 of IDE397 in combination with Trodelvy  in MTAP-deletion UC and clinical data update in 2025; expanded clinical study collaboration into NSCLC. \"We had multiple positive clinical updates across our pipeline throughout the past year that were presented at major medical conferences, including compelling results such as tumor shrinkage and eye preservation for neoadjuvant darovasertib which was presented as an oral presentation at ASCO 2024, and evidence for monotherapy activi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ideaya-biosciences-inc-reports-fourth-110500658.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ideaya-biosciences-inc-reports-fourth-110500658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IDYA","MSS","PFS","BK4113","ADC","BK4097","BK4080","BK4231","BK4195","BK4211","OS"],"gpt_icon":0},{"id":"2511548522","title":"OneStream Full Year 2024 Earnings: EPS Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2511548522","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511548522?lang=en_us&edition=fundamental","pubTime":"2025-02-13 18:21","pubTimestamp":1739442087,"startTime":"0","endTime":"0","summary":"NasdaqGS:OS Earnings and Revenue Growth February 13th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue was in line with analyst estimates. Earnings per share  surpassed analyst estimates by 25%.Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Software industry in the US.The company's shares are down 19% from a week ago.Before you take the next step you should know about the 1 warning sign for OneStream that we have uncovered.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onestream-full-2024-earnings-eps-102127989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS"],"gpt_icon":0},{"id":"2511530408","title":"Onestream Inc. A: Positive Earnings Call Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2511530408","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511530408?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:19","pubTimestamp":1739405959,"startTime":"0","endTime":"0","summary":"Onestream, Inc. Class A (($OS)) has held its Q4 earnings call. Read on for the main highlights of the call. The latest earnings call from Onestream...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/onestream-inc-a-positive-earnings-call-insights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/onestream-inc-a-positive-earnings-call-insights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OS"],"gpt_icon":0},{"id":"2511580078","title":"Why OneStream Inc. (OS) Stock Is Crashing Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2511580078","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511580078?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:17","pubTimestamp":1739395060,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 10 Trending AI News Updates And Analyst Ratings. In this article, we are going to take a look at where OneStream Inc.  stands against other top trending AI news updates and analyst ratings.The US AI industry is witnessing a wave of new developments led by Elon Musk’s $97 billion bid to takeover OpenAI, the same company he co-founded with Sam Altman. The OpenAI CEO rejected that offer and added that Musk is acting out of insecurity rather than genuine interest.The engagement got interesting when Altman counteroffered to buy X.com for $9.74 billion. The clash between the two AI leaders is ongoing amid a broader power struggle over the future of AI.On February 11th, OneStream Inc.  beat Q4 2024 revenue estimates of $128.1 million with a $132.5 million print. The company posted an EPS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-onestream-inc-os-stock-211740235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","USJW.SI","QID","TSYW.SI","MNQmain","QLD","BK4097","USAW.SI","NQmain","PSQ","OS","SQQQ","TQQQ","NVIW.SI"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2024-09-03","symbol":"OS","fiscalQuarterEnding":"2024/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5714,"hold":0.0952,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1748491200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-06-13","current":-21.083062,"percent":0.688372,"low":-1655.61542,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"high":-14.493656,"avg":-366.615877,"sd":586.069132,"marketCap":4959958960},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960}],"updateTime":1750121029535}}}